skip to content

EPSRC IRC in Targeted Delivery for Hard-to-Treat Cancers

 

 

The Interdisciplinary Research Collaboration’s (IRC) Cancer in Sight blog series shares the latest thinking from the IRC in Targeted Delivery for Hard-to-Treat Cancers. Our monthly blogs bring insights, comment and opinion from scientists, engineers, clinicians and industry partners working to better target delivery of drugs for hard-to-treat cancers. The inaugural Cancer in Sight blog is written by George Malliaras, Prince Philip Professor of Technology and Director of the IRC programme at the University of Cambridge.

 

Read more at: March 2024: Building capacity: how the IRC is equipping early career researchers

March 2024: Building capacity: how the IRC is equipping early career researchers


Read more at: October 2023: Brain tumour research – a critical priority

October 2023: Brain tumour research – a critical priority


Read more at: September 2023: Chicken, egg and mesothelioma

September 2023: Chicken, egg and mesothelioma



Read more at: November 2022: Living with pancreatic cancer – a patient's perspective

November 2022: Living with pancreatic cancer – a patient's perspective


Read more at: October 2022: Targeted delivery – taking a multidisciplinary approach towards a shared goal  

October 2022: Targeted delivery – taking a multidisciplinary approach towards a shared goal  


Read more at: September 2022: Direct delivery – metal organic frameworks to target hard-to-treat cancers 

September 2022: Direct delivery – metal organic frameworks to target hard-to-treat cancers 



Read more at: August 2022: Pathway to a Cure – overcoming barriers to funding for brain tumour research

August 2022: Pathway to a Cure – overcoming barriers to funding for brain tumour research


Read more at: July 2022: Taking a multidisciplinary approach to better target mesothelioma

July 2022: Taking a multidisciplinary approach to better target mesothelioma


Read more at: June 2022: Mesothelioma and me

June 2022: Mesothelioma and me



Read more at: Spreading the scientific word: how effective outreach helps shape diversity in multidisciplinary teams

Spreading the scientific word: how effective outreach helps shape diversity in multidisciplinary teams


Read more at: April 2022: Transporting precious cargo – the critical importance of drug delivery to target hard-to-treat cancers

April 2022: Transporting precious cargo – the critical importance of drug delivery to target hard-to-treat cancers


Read more at: March 2022: From science fiction to science fact – the emergence of nanotechnology for hard-to-treat cancers

March 2022: From science fiction to science fact – the emergence of nanotechnology for hard-to-treat cancers



Read more at: February 2022: adding additive manufacturing to personalised and controlled drug release from implantable pumps

February 2022: adding additive manufacturing to personalised and controlled drug release from implantable pumps


Read more at: January 2022: Engaging a clinical line of sight to target pancreatic cancer

January 2022: Engaging a clinical line of sight to target pancreatic cancer


Read more at: December 2021: Looking to the future – while living with glioblastoma

December 2021: Looking to the future – while living with glioblastoma



Read more at: November 2021: Ahead of the game – the role of design for manufacturing on the path from laboratory to clinic

November 2021: Ahead of the game – the role of design for manufacturing on the path from laboratory to clinic


Read more at: October 2021: Understanding the urgency of research in drug delivery for hard-to-treat cancers

October 2021: Understanding the urgency of research in drug delivery for hard-to-treat cancers


Read more at: September 2021: Why a multi-disciplinary approach to targeted delivery brings benefits and challenges

September 2021: Why a multi-disciplinary approach to targeted delivery brings benefits and challenges



Read more at: Inaugural Blog: Taking the long-term view to make short work of cancer

Inaugural Blog: Taking the long-term view to make short work of cancer